/TAK
Takeda Pharmaceutical Company Limited
TAK • NYSETAK • NYSE • Healthcare
$18.22+0.77%+0.14
$18.22+0.77%(+0.14)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
70Bullish
Risk
100Low Risk
Momentum
90Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
65.5%▼0.9pp
Revenue after COGS
Operating
7.5%▲2.5pp
After operating expenses
Net
2.4%▼1.0pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
66.3
Price vs earnings
EV/EBITDA
9.3
Enterprise value
FCF Yield
12.0%
Cash generation
Earnings Yield
1.5%
Inverse of P/E
Capital Efficiency
1
GoAI Quality ScoreWeak
ROEReturn on Equity
1.6%Fair
ROAReturn on Assets
0.8%Fair
ROICReturn on Invested Capital
1.7%Fair
Financial Health
Current RatioAdequate
1.01
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
3.41x
Debt repayment capacity (<3x)
Income QualityStrong
9.80
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.58T | $4.26T | $4.03T | $3.57T | $3.20T |
| Gross Profit | $3.00T | $2.83T | $2.78T | $2.46T | $2.20T |
| Gross Margin | 65.5% | 66.4% | 69.1% | 69.0% | 68.9% |
| Operating Income | $342.59B | $214.07B | $490.50B | $460.84B | $509.27B |
| Net Income | $107.93B | $144.07B | $317.02B | $230.06B | $376.00B |
| Net Margin | 2.4% | 3.4% | 7.9% | 6.4% | 11.8% |
| EPS | $34.17 | $46.05 | $102.15 | $73.57 | $120.36 |
Rating Distribution
Strong Buy
0
0%
Buy
5
83%
Hold
1
17%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
TD Cowen● Maintain
Outperform
2023-05-16TD Cowen● Maintain
Outperform
2023-05-15TD Cowen● Maintain
Outperform
2023-04-04TD Cowen● Maintain
Outperform
2023-04-03B of A Securities▲ Upgrade
Neutral→Buy
2023-03-16B of A Securities▲ Upgrade
Neutral→Buy
2023-03-15Cowen & Co.▲ Upgrade
Market Perform→Outperform
2022-07-19Cowen & Co.▲ Upgrade
Market Perform→Outperform
2022-07-18Morgan Stanley▼ Downgrade
Overweight→Equal Weight
2021-10-07Morgan Stanley▼ Downgrade
Overweight→Equal Weight
2021-10-06Earnings History & Surprises
BEAT RATE
63%
Last 16 quarters
AVG SURPRISE
+127.0%
EPS vs Estimate
BEATS / MISSES
10/5
1 met exactly
LATEST EPS
$0.48
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-12.7%
$0.48 vs $0.55
Q4 '25
$0.44 vs $0.44
Q3 '25
+10.6%
$0.52 vs $0.47
Q2 '25
No data
Q1 '25
-33.3%
$0.42 vs $0.63
Q4 '24
+12.8%
$0.44 vs $0.39
Q3 '24
+51.4%
$0.56 vs $0.37
Q2 '24
-330.5%
$-0.01 vs $0.00
Q1 '24
+420.5%
$0.51 vs $0.10
Q4 '23
+418.1%
$0.50 vs $0.10
Q3 '23
+287.9%
$0.55 vs $0.14
Q2 '23
+672.4%
$0.39 vs $0.05
No investor questions available.
Latest News
No news available